IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: YARIV DONDE, et al.	Examiner: Robert Gerstl (parent appl.)
Serial No.: Pending	Group Art Unit: 1626 (parent appl.)
Filed: Herewith	
For: 10,10-DIALKYL PROSTANOIC ACID) DERIVATIVES AS AGENTS FOR LOWERING) INTRAOCULAR PRESSURE	Irvine, California

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

Applicants provide with regard to the patent application entitled, 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE filed herewith one copy of a documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 1 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: February 4, 2004

Brent A. Johnson

Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson Allergan, Inc. 2525 Dupont Drive, T2-7H Irvine, California 92623-9534

Tel: (714) 246-4348 Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date February 4, 2004, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV193720773US addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Susan Bartholomew
Name of person mailing paper

Date: February 4, 2004

Cianatura of narron mailing nano

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17540CIP (AP)	SERIAL NO.: Pending
APPLICANTS:	YARIV DONDE, et al.	TITLE: 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE N
FILING DATE:	HEREWITH	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicabl)
	AA	4,117,014	9/26/78	Pernet, et al.			
	AB	4,994,274	2/19/91	Chan, et al.			
	AC	5,034,413	7/23/91	Chan, et al.			
	AD	5,446,041	8/29/95	Chan, et al.			
	AE	6,531,504 B2	3/11/03	Burk, et al.			
	AF	07/175,476		Chan, et al.			12/29/93
	AG						
	AH						,

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
ВА	59-101458	6-12-84	Japan			N
ВВ						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Bito, L.Z., <i>Prostaglandins old concepts and new perspectives</i> , Arch Ophthalmol – Vol 105, Aug 1987, pp. 1036-10-39
СВ	Bito, L.Z., <i>Prostaglandins and related compounds as potential ocular therapeutic agents</i> , Chpt. 18, Biological Protection with Prostaglandins, Vol. 1, CRC Press, Inc., M.M. Cohen, Editor.
CC	Bito, L.Z., <i>Prostaglandins, other eicosanoids, and their derivatives as potential antiglaucoma agents</i> , Chap. 20, pp. 477-505, Glaucoma: Applied pharmacology in medical treatment, Grune & Stratton, Inc., S.Drance, et al., Editors.
CD	Brooks, D.W., et al., Asymmetric Microbial Reduction of prochiral 2,2-disubstituted cycloalkanediones, J. Org. Chem. 1987, 52, 3223-3232
CE	Nilsson, S., et al, <i>PGF</i> ₂ , <i>Increases uveoscleral outflow</i> , Invest Ophthalmol Vis Sci 1987; 28(3 Suppl) :284

EXAMINER						DATE	CON	ISIDEI	REL)			
**************************************				_	-								 _

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.